Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Case Report WIN-MTB-2023001 WIN International Molecular Tumor Board A 62-year-old male with metastatic colorectal cancer with 5 prior lines of treatment.

Oncotarget - 17 Jun 2025

Hernando-Calvo Alberto, Kurzrock Razelle, Gonzalez Nadia Saoudi, Magidi Shai, Bresson Catherine, Wunder Fanny, Pretelli Giulia, Casado Agatha Martin, El-Deiry Wafik S

Abstract excerpt

Heavily pretreated metastatic colorectal cancer (mCRC) poses significant therapeutic challenges. Advances in molecular profiling enables personalized strategies. We present a 62-year-old male with mCRC harboring BRAF, MET, APC, TP53 and NRAS alterations, following FOLFOX and FOLFIRI, dabrafenib plus panitumumab, and a BRAF inhibitor clinical trial, each leading to initial responses followed by disease...

Topics

Join the communities discussing this publication.

Antineoplastic Combined Chemotherapy Protocols
Biomarkers, Tumor
Camptothecin
Colorectal Neoplasms
Fluorouracil

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Neoplasm Metastasis

Source

Open in PubMed Open full text

Identifiers

PMID: 40526090
DOI: 10.18632/oncotarget.28744
PMCID: PMC12175699

Genes

MET
BRAF
EGFR
APC
TP53
NRAS

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Case Report WIN-MTB-2023001 WIN International Molecular Tumor Board A 62-year-old male with metastatic colorectal cancer with 5 prior lines of treatment.PMID 40526090Read ↗

A perspective on emerging therapies in metastatic colorectal cancer: Focusing on molecular medicine and drug resistanceSemantic proximity Read ↗

Retrospective Analysis of Treatment Pathways in Patients With BRAFV600E-mutant Metastatic Colorectal Carcinoma - MORSECRC.Semantic proximity Read ↗

A Comprehensive Review of Sequencing and Combination Strategies of Targeted Agents in Metastatic Colorectal Cancer.Semantic proximity Read ↗

Molecular profiling of 6,892 colorectal cancer samples suggests different possible treatment options specific to metastatic sites.Semantic proximity Read ↗

European expert panel consensus on the clinical management of BRAFV600E-mutant metastatic colorectal cancer.Semantic proximity Read ↗

BRAF-Mutated Colorectal Cancer: Clinical and Molecular Insights.Semantic proximity Read ↗

Updates in the Treatment of Metastatic Colorectal CancerSemantic proximity Read ↗

Molecular-Biology-Driven Treatment for Metastatic Colorectal CancerSemantic proximity Read ↗

Therapeutic landscape and future direction of metastatic colorectal cancer.Semantic proximity Read ↗

Update on optimal treatment for metastatic colorectal cancer from the ACTG/AGITG expert meeting: ECCO 2015.Semantic proximity Read ↗

Real-World Outcomes of First-line and Second-line Chemotherapy with Dabrafeniband Cetuximab in BRAF V600E-Mutant Metastatic Colorectal Cancer: The Preliminary Data from a Single CenterSemantic proximity Read ↗

Cobimetinib Plus Vemurafenib in Patients With Colorectal Cancer With BRAF Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.